Yes , and that was just for a two month advantage in survival rate . On early stage NSCLC non refractory disease , with another chemo . Does not compare with the response that Solbec got against late stage 4 NSCLC disease that was refractory , as a stand alone treatment . That is of course assuming it can be duplicated , but the indications are good . One NSCLC patient and one good response .
As I have said before Robert Nagourneys assay tests years ago predicted this potent mode of action against NSCLC as a single agent .
<
SBP002 44%
CDDP/Gem 22%
5Fu/Nav 11%
5Fu/Gem 11%
Carbo/Tax 11%
MMC/5Fu 11%
5Fu/CDDP 11%
Gem/Topo/CDDP 11%
Nav 11% >>
Remember the RT tests are on fresh human tumour assays ex-vivo , so the rate you see above should be further boosted by the now proven immune system attack on the tumour site , that starts as the immune system recognises the tumour , once the tumour cell fragments destroyed by the Coramsine come into contact with the immune system . That part of it seems very similar to how vaccines work to me .
That DNA $11billion market cap increase , on the back of a fairly small improvement against NSCLC augers well for Solbecs future . Current market cap looks just a tad too low IMHO .
Cheers
- Forums
- ASX - By Stock
- SBP
- genentech up $11 billion
SBP
solbec pharmaceuticals limited
genentech up $11 billion, page-2
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SBP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online